04.03.2025 • NewsAbbVieobesitylicense agreement

AbbVie Teams up with Gubra to Develop Obesity Treatment

The US pharmaceutical giant AbbVie and Danish biotechnology company Gubra, specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, signed a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.

GUB014295 is currently in a Phase 1 clinical trial. A potential long-acting amylin analog, the compound is an agonist that specifically activates amylin and calcitonin receptors. Amylin, a satiety hormone, has been identified as a potential therapeutic target for the treatment of obesity given its role in activating signals to the brain that result in appetite suppression and the reduction of food intake, while also acting as an inhibitory signal to delay gastric emptying.

Under the terms of the agreement, AbbVie will lead development and commercialization activities of GUB014295 globally. Gubra will receive $350 million in total upfront payment and will be eligible to receive up to $1.875 billion in development, commercial and sales milestone payments with tiered royalties on global net sales, the companies said. The transaction closure is subject to regulatory approvals and other customary closing conditions.

© Tero Vesalainen/Shutterstock
© Tero Vesalainen/Shutterstock

"At AbbVie, we are focused on transforming the future of patient care in areas where significant unmet need persists," said Robert A. Michael, AbbVie’s CEO. "Our partnership with Gubra marks our entry into the obesity field, offering a compelling opportunity based on the potential to address patient needs while also fostering long-term growth for our company."

Henrik Blou, CEO of Gubra, added: "This collaboration between Gubra and AbbVie will accelerate the development of GUB014295 and build on the promising data shown in its Phase 1 single ascending dose (SAD) trial."

"Obesity represents a significant global health concern with nearly 900 million adults with obesity, many of whom struggle to stay on current treatment options," said Roopal Thakkar, executive vice president, research & development and chief scientific officer at AbbVie.

Company

Logo:

AbbVie Inc.


North Chicago, Illinois
US

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read